Wladimir Hogenhuis Purchases 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis bought 10,000 shares of Rezolute stock in a transaction on Tuesday, February 18th. The shares were purchased at an average cost of $4.70 per share, with a total value of $47,000.00. Following the acquisition, the director now directly owns 77,267 shares of the company’s stock, valued at approximately $363,154.90. The trade was a 14.87 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Rezolute Stock Up 1.8 %

Rezolute stock traded up $0.08 during midday trading on Thursday, reaching $4.63. The company’s stock had a trading volume of 337,775 shares, compared to its average volume of 529,148. Rezolute, Inc. has a fifty-two week low of $1.45 and a fifty-two week high of $6.19. The company has a market cap of $280.28 million, a P/E ratio of -3.80 and a beta of 1.10. The business has a 50-day simple moving average of $4.84 and a 200-day simple moving average of $4.90.

Rezolute (NASDAQ:RZLT) last posted its earnings results on Wednesday, February 12th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. As a group, equities analysts forecast that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Institutional Trading of Rezolute

A number of hedge funds and other institutional investors have recently made changes to their positions in RZLT. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Rezolute during the third quarter worth about $65,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Rezolute during the third quarter worth about $239,000. State Street Corp increased its position in shares of Rezolute by 11.6% during the third quarter. State Street Corp now owns 125,472 shares of the company’s stock worth $609,000 after purchasing an additional 13,000 shares in the last quarter. XTX Topco Ltd increased its position in shares of Rezolute by 67.4% during the third quarter. XTX Topco Ltd now owns 56,375 shares of the company’s stock worth $273,000 after purchasing an additional 22,704 shares in the last quarter. Finally, MML Investors Services LLC acquired a new stake in shares of Rezolute during the third quarter worth about $57,000. Institutional investors and hedge funds own 82.97% of the company’s stock.

Analysts Set New Price Targets

RZLT has been the subject of a number of research analyst reports. Guggenheim reissued a “buy” rating on shares of Rezolute in a report on Monday, February 10th. Wedbush reaffirmed an “outperform” rating and issued a $112.00 price target on shares of Rezolute in a report on Monday, November 4th. JMP Securities increased their price target on Rezolute from $8.00 to $9.00 and gave the company a “market outperform” rating in a report on Thursday, February 13th. Craig Hallum upgraded Rezolute to a “strong-buy” rating in a research report on Tuesday, February 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research report on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Rezolute has a consensus rating of “Buy” and an average target price of $24.38.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.